Supernus Pharma Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Supernus Pharma has an operating margin of 12.3%, meaning the company retains $12 of operating profit per $100 of revenue. This results in a moderate score of 62/100, indicating healthy but not exceptional operating efficiency. This is up from -0.9% the prior year.
Supernus Pharma's revenue grew 8.9% year-over-year to $661.8M, a solid pace of expansion. This earns a growth score of 54/100.
Supernus Pharma carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.35, Supernus Pharma holds $2.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.
Supernus Pharma converts 25.9% of revenue into free cash flow ($171.2M). This strong cash generation earns a score of 100/100.
Supernus Pharma generates a 7.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 29/100. This is up from 0.1% the prior year.
Supernus Pharma scores 6.86, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.9B) relative to total liabilities ($332.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Supernus Pharma passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Supernus Pharma generates $2.33 in operating cash flow ($172.0M OCF vs $73.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
This page shows Supernus Pharma (SUPN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Supernus Pharma generated $661.8M in revenue in fiscal year 2024. This represents an increase of 8.9% from the prior year.
Supernus Pharma's EBITDA was $162.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 103.6% from the prior year.
Supernus Pharma generated $171.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 54.9% from the prior year.
Supernus Pharma reported $73.9M in net income in fiscal year 2024. This represents an increase of 5512.8% from the prior year.
Supernus Pharma earned $1.32 per diluted share (EPS) in fiscal year 2024. This represents an increase of 6500.0% from the prior year.
Supernus Pharma held $69.3M in cash against $0 in long-term debt as of fiscal year 2024.
Supernus Pharma had 56M shares outstanding in fiscal year 2024. This represents an increase of 1.9% from the prior year.
Supernus Pharma's gross margin was 88.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.0 percentage points from the prior year.
Supernus Pharma's operating margin was 12.3% in fiscal year 2024, reflecting core business profitability. This is up 13.2 percentage points from the prior year.
Supernus Pharma's net profit margin was 11.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 10.9 percentage points from the prior year.
Supernus Pharma's ROE was 7.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 7.0 percentage points from the prior year.
Supernus Pharma invested $108.8M in research and development in fiscal year 2024. This represents an increase of 18.8% from the prior year.
Supernus Pharma invested $725K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 31.6% from the prior year.
SUPN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.1M+16.1% | $165.5M+10.4% | $149.8M-14.0% | $174.2M+3.5% | $168.3M+17.2% | $143.6M-12.6% | $164.3M+6.8% | $153.9M |
| Cost of Revenue | $19.0M+12.7% | $16.8M+6.7% | $15.8M-39.6% | $26.1M+45.7% | $17.9M+9.9% | $16.3M-16.9% | $19.6M+0.1% | $19.6M |
| Gross Profit | $173.1M+16.5% | $148.6M+10.9% | $134.1M-9.5% | $148.1M-1.6% | $150.4M+18.1% | $127.3M-12.0% | $144.7M+7.8% | $134.3M |
| R&D Expenses | $29.4M+32.8% | $22.1M-17.9% | $26.9M-6.0% | $28.6M+9.4% | $26.2M+5.0% | $24.9M+6.8% | $23.3M+3.1% | $22.7M |
| SG&A Expenses | $179.7M+92.1% | $93.6M+4.0% | $89.9M+13.3% | $79.4M-7.6% | $85.9M-0.7% | $86.5M+6.4% | $81.3M-1.7% | $82.7M |
| Operating Income | -$60.2M-596.1% | $12.1M+218.4% | -$10.3M-147.9% | $21.4M-5.2% | $22.6M+815.8% | -$3.2M-216.6% | -$996K-112.2% | $8.1M |
| Interest Expense | N/A | N/A | N/A | $0 | $0 | $0+100.0% | -$1.1M | $0 |
| Income Tax | -$12.8M-120.2% | -$5.8M-197.2% | $6.0M-45.8% | $11.1M+73.1% | $6.4M+5266.4% | $119K+164.3% | -$185K-100.7% | $25.9M |
| Net Income | -$45.1M-300.5% | $22.5M+290.2% | -$11.8M-177.2% | $15.3M-23.0% | $19.9M+15961.3% | $124K-89.4% | $1.2M+107.4% | -$16.0M |
| EPS (Diluted) | $-0.80-300.0% | $0.40+290.5% | $-0.21-177.8% | $0.27-25.0% | $0.36 | $0.00-100.0% | $0.04+113.8% | $-0.29 |
SUPN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+2.7% | $1.4B+2.6% | $1.3B-1.5% | $1.4B+4.0% | $1.3B+0.9% | $1.3B+2.1% | $1.3B-0.6% | $1.3B |
| Current Assets | $593.9M-19.6% | $738.9M+7.5% | $687.6M+0.2% | $686.1M+16.1% | $591.0M+8.6% | $544.3M+10.4% | $493.1M+9.7% | $449.4M |
| Cash & Equivalents | $151.4M+4.6% | $144.7M+24.9% | $115.8M+67.1% | $69.3M+33.1% | $52.1M-17.8% | $63.4M-15.5% | $75.1M-21.0% | $95.0M |
| Inventory | $107.1M+143.3% | $44.0M-10.9% | $49.4M-9.0% | $54.3M-20.3% | $68.2M-9.2% | $75.1M-3.0% | $77.4M-7.3% | $83.5M |
| Accounts Receivable | $171.3M+21.6% | $140.8M-3.3% | $145.6M+2.5% | $142.1M-6.8% | $152.5M+3.2% | $147.7M+2.5% | $144.2M+1.7% | $141.8M |
| Goodwill | $119.1M+1.8% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M0.0% | $117.0M |
| Total Liabilities | $370.1M+16.2% | $318.5M+0.6% | $316.6M-4.7% | $332.3M-7.3% | $358.4M-4.4% | $374.9M+5.3% | $356.2M-4.5% | $373.0M |
| Current Liabilities | $330.6M+15.5% | $286.4M+1.6% | $281.8M-3.6% | $292.4M-5.3% | $308.7M-1.9% | $314.6M+8.4% | $290.2M+0.9% | $287.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.0B-1.3% | $1.1B+3.2% | $1.0B-0.5% | $1.0B+8.2% | $957.5M+3.0% | $929.2M+0.8% | $921.5M+1.0% | $912.2M |
| Retained Earnings | $522.0M-8.0% | $567.1M+4.1% | $544.6M-2.1% | $556.4M+10.7% | $502.6M+4.1% | $482.7M0.0% | $482.6M+0.2% | $481.4M |
SUPN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$61.7M-205.3% | $58.5M+91.3% | $30.6M-31.1% | $44.4M+24.7% | $35.6M-7.2% | $38.4M-14.6% | $45.0M+25.3% | $35.9M |
| Capital Expenditures | $129K-71.6% | $455K+39.1% | $327K+53.5% | $213K+232.8% | $64K-74.2% | $248K+788.9% | -$36K-124.0% | $150K |
| Free Cash Flow | -$61.8M-206.4% | $58.1M+91.9% | $30.3M-31.5% | $44.2M+24.3% | $35.6M-6.8% | $38.2M-15.1% | $44.9M+25.7% | $35.7M |
| Investing Cash Flow | $48.7M+259.1% | -$30.6M-182.0% | $37.3M+395.3% | -$12.6M+74.0% | -$48.6M+5.9% | -$51.6M+21.8% | -$66.0M-290.5% | $34.6M |
| Financing Cash Flow | $21.1M+2153.3% | $935K+104.4% | -$21.4M-463.3% | $5.9M+255.2% | $1.7M+5.6% | $1.6M+43.8% | $1.1M+574.8% | -$230K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SUPN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.1%+0.3pp | 89.8%+0.3pp | 89.5%+4.5pp | 85.0%-4.3pp | 89.4%+0.7pp | 88.6%+0.6pp | 88.1%+0.8pp | 87.3% |
| Operating Margin | -31.4%-38.7pp | 7.3%+14.2pp | -6.9%-19.1pp | 12.3%-1.1pp | 13.4%+15.6pp | -2.2%-1.6pp | -0.6%-5.9pp | 5.3% |
| Net Margin | -23.5%-37.1pp | 13.6%+21.5pp | -7.9%-16.7pp | 8.8%-3.0pp | 11.8%+11.7pp | 0.1%-0.6pp | 0.7%+11.1pp | -10.4% |
| Return on Equity | N/A | 2.1% | N/A | 1.5%-0.6pp | 2.1%+2.1pp | 0.0%-0.1pp | 0.1% | N/A |
| Return on Assets | -3.2%-4.8pp | 1.6%+2.5pp | -0.9%-2.0pp | 1.1%-0.4pp | 1.5%+1.5pp | 0.0%-0.1pp | 0.1%+1.3pp | -1.2% |
| Current Ratio | 1.80-0.8 | 2.58+0.1 | 2.44+0.1 | 2.35+0.4 | 1.91+0.2 | 1.73+0.0 | 1.70+0.1 | 1.56 |
| Debt-to-Equity | 0.35+0.1 | 0.300.0 | 0.31-0.0 | 0.32-0.1 | 0.37-0.0 | 0.40+0.0 | 0.39-0.0 | 0.41 |
| FCF Margin | -32.2%-67.3pp | 35.1%+14.9pp | 20.2%-5.2pp | 25.4%+4.3pp | 21.1%-5.4pp | 26.6%-0.8pp | 27.3%+4.1pp | 23.2% |
Similar Companies
Frequently Asked Questions
What is Supernus Pharma's annual revenue?
Supernus Pharma (SUPN) reported $661.8M in total revenue for fiscal year 2024. This represents a 8.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Supernus Pharma's revenue growing?
Supernus Pharma (SUPN) revenue grew by 8.9% year-over-year, from $607.5M to $661.8M in fiscal year 2024.
Is Supernus Pharma profitable?
Yes, Supernus Pharma (SUPN) reported a net income of $73.9M in fiscal year 2024, with a net profit margin of 11.2%.
What is Supernus Pharma's earnings per share (EPS)?
Supernus Pharma (SUPN) reported diluted earnings per share of $1.32 for fiscal year 2024. This represents a 6500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Supernus Pharma's EBITDA?
Supernus Pharma (SUPN) had EBITDA of $162.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Supernus Pharma's gross margin?
Supernus Pharma (SUPN) had a gross margin of 88.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Supernus Pharma's operating margin?
Supernus Pharma (SUPN) had an operating margin of 12.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Supernus Pharma's net profit margin?
Supernus Pharma (SUPN) had a net profit margin of 11.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Supernus Pharma's return on equity (ROE)?
Supernus Pharma (SUPN) has a return on equity of 7.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Supernus Pharma's free cash flow?
Supernus Pharma (SUPN) generated $171.2M in free cash flow during fiscal year 2024. This represents a 54.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Supernus Pharma's operating cash flow?
Supernus Pharma (SUPN) generated $172.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Supernus Pharma's total assets?
Supernus Pharma (SUPN) had $1.4B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Supernus Pharma's capital expenditures?
Supernus Pharma (SUPN) invested $725K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Supernus Pharma spend on research and development?
Supernus Pharma (SUPN) invested $108.8M in research and development during fiscal year 2024.
How many shares does Supernus Pharma have outstanding?
Supernus Pharma (SUPN) had 56M shares outstanding as of fiscal year 2024.
What is Supernus Pharma's current ratio?
Supernus Pharma (SUPN) had a current ratio of 2.35 as of fiscal year 2024, which is generally considered healthy.
What is Supernus Pharma's debt-to-equity ratio?
Supernus Pharma (SUPN) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Supernus Pharma's return on assets (ROA)?
Supernus Pharma (SUPN) had a return on assets of 5.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Supernus Pharma's Altman Z-Score?
Supernus Pharma (SUPN) has an Altman Z-Score of 6.86, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Supernus Pharma's Piotroski F-Score?
Supernus Pharma (SUPN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Supernus Pharma's earnings high quality?
Supernus Pharma (SUPN) has an earnings quality ratio of 2.33x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Supernus Pharma?
Supernus Pharma (SUPN) scores 70 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.